NCT00407212 - A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy | Biotech Hunter

Enrollment

301

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions

Parkinson's Disease

Interventions

DRUG

TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)

Trial Locations (45)

Unknown

Phoenix

Berkley

Fountain Valley

Sunnyvale

New Haven

Chicago

Southfield

Great Falls

Columbus

Pawtucket

Houston

Novartis Investigative Site, Belo Horizonte

Novartis Investigative Site, Curitiba

Novartis Investigative Site, Fortaleza

Novartis Investigative Site, São Paulo

Novartis Investigative Site, Caligary

Novartis Investigative Site, Hallifax

Novartis Investigative Site, Markham

Novartis Investigative Site, Montreal

Novartis Investigative Site, Vancouver

Novartis Investigative Site, Winnipeg

Novartis Investigative Site, Clermont

Marseille

Novartis Investigative Site, Paris

Saint-Herblain

Tours

Berlin

Bochum

Leipzig

Wiesbaden

Genova

Lido di Camaiore

Maples

Milan

Pescara

's-Hertogenbosch

Amsterdam

Bedra

Biaricum

Dordrecht

Groningen

Lisbon

Birmingham

Cambridge

Sheffield